OverviewSuggest Edit

Motif Bio PLC is a United Kingdom-based clinical-stage biopharmaceutical company which specializes in developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, Iclaprim, and MTF-001, a preclinical program.-based on iclaprim and other lead compounds, the Company is engaged in the development of a lead series with the objective of identifying a DHFRi that is effective against a broad spectrum of gram positive bacteria, including those resistant to available antibiotics, that can be administered once daily in injectable (I/V) and oral (pill) formulations. The Company's other programs include programs in various-stages of development by building a portfolio of antibiotics by licensing drug candidates from organizations specialized in antibacterial research.
TypePublic
HQLondon, GB
Websitemotifbio.com

Latest Updates

Employees (est.) (Sept 2020)7
Share Price (Oct 2020)£0
Cybersecurity ratingAMore

Key People/Management at Motif Bio

Bruce Williams

Bruce Williams

Chairman

Motif Bio Office Locations

Motif Bio has offices in London and New York
London, GB (HQ)
3-7 Temple Avenue, Temple
New York, US
125 Park Ave #2622
Show all (2)

Motif Bio Financials and Metrics

Motif Bio Revenue

GBP

Net income (FY, 2018)

(10.7m)

EBITDA (FY, 2018)

(14.3m)

EBIT (FY, 2018)

(14.3m)

Market capitalization (20-Oct-2020)

3.3m

Closing stock price (20-Oct-2020)

0.0

Cash (31-Dec-2018)

9.4m
Motif Bio's current market capitalization is £3.3 m.
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

EBITDA

(749.9k)(6.3m)(28.2m)(29.1m)(14.3m)

EBIT

(749.9k)(6.3m)(28.2m)(29.1m)(14.3m)

Pre tax profit

(810.8k)(6.5m)(28.7m)(34.3m)(10.7m)

Income tax expense

(599.3)(587.1)(204.5)(16.9k)(6.9k)
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.2k21.7m15.6m17.4m9.4m

Accounts Receivable

8.2k

Current Assets

154.6k21.8m15.8m17.6m9.6m

Goodwill

4.2m
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(811.4k)(6.5m)(28.7m)(34.3m)(10.7m)

Cash From Operating Activities

(1.1k)(6.1m)(19.9m)(28.7m)(16.4m)

Cash From Financing Activities

3.4k27.8m15.3m29.5m8.6m

Net Change in Cash

2.2k21.7m(4.6m)780.9k(7.8m)
Show all financial metrics

Motif Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Motif Bio Online and Social Media Presence

Embed Graph

Motif Bio News and Updates

Motif Bio Presents New Iclaprim Data at ASM Microbe 2019

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new iclaprim data were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting held in Sa…

Motif Bio plc AGM Statement

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier today the Company provided the following review of key aspects of its business and …

Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating i…

Motif Bio to Present Iclaprim Data at ASM Microbe 2019

NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology …

Motif Bio meeting with U.S. FDA held as planned

NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met with the U.S. Food & Drug Administration (FDA) on May 3, 2019 as expected. The Type A meeting was …

Motif Bio Signs Agreement with Lamellar Biomedical

Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections
Show more

Motif Bio Blogs

Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market

Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market Content Import Tue, 11/26/2019 - 02:00 Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market November 26, 2019 at 2:00 AM EST This release is a backfill from a News…

Settlement Agreement

Motif Bio plc (AIM/Nasdaq: MTFB) announces that its subsidiary Motif BioSciences Inc., has reached agreement with its former clinical research organisation to settle all obligations without further payment.  This will result in the reversal of a previously recognised expense and the reduction of

Motif Bio confirms receipt of FDA meeting minutes

Motif Bio confirms receipt of FDA meeting minutes James.Jordan@n… Thu, 10/10/2019 - 02:00 Motif Bio confirms receipt of FDA meeting minutes October 10, 2019 at 2:00 AM EDT This release is a backfill from a News Wire RNS Backfill RNS N…

Motif Bio Reports Half-Year 2019 Financial Results, Operational Progress and Proposed Initiatives

Motif Bio plc (AIM/NASDAQ: MTFB) today announced unaudited financial results for the half year ended June 30, 2019 and reported on its progress year to date. Graham Lumsden, CEO of Motif Bio, said: "Receipt in February of the CRL for iclaprim dealt a major blow to our wholly-owned subsidiary, Motif

Motif Bio and Hercules Capital Amend Loan and Security Agreement

NEW YORK , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its Lender, Hercules Capital, Inc. , has agreed to amend the Company’s loan and security agreement such that

Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq

Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq Content Import Fri, 07/26/2019 - 02:00 Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq July 26, 2019 at 2:00 AM EDT This release is a backfill from a News Wire General …
Show more

Motif Bio Frequently Asked Questions

  • Who are Motif Bio key executives?

    Motif Bio's key executives are Bruce Williams.

  • How many employees does Motif Bio have?

    Motif Bio has 7 employees.

  • Who are Motif Bio competitors?

    Competitors of Motif Bio include Array BioPharma, Durect and BTG.

  • Where is Motif Bio headquarters?

    Motif Bio headquarters is located at 3-7 Temple Avenue, Temple, London.

  • Where are Motif Bio offices?

    Motif Bio has offices in London and New York.

  • How many offices does Motif Bio have?

    Motif Bio has 2 offices.